Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S.
Bühler A, et al. Among authors: gregory sa.
Blood Cancer J. 2016 Mar 11;6(3):e404. doi: 10.1038/bcj.2016.9.
Blood Cancer J. 2016.
PMID: 26967821
Free PMC article.
Clinical Trial.